Business description: ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Number of employees: 73

Sales by Activity: ImmuCell Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Scours

- 18.41M 17.29M 26.31M 27.45M

Mastitis

- 155K 178K 179K 196K

Biotechnology

19.24M - - - -

Other

- 1.46K - - -

Geographical breakdown of sales: ImmuCell Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

16.62M 17.02M 15.95M 22.89M 24.39M

Other

2.62M 1.55M 1.52M 3.6M 3.25M

Executive Committee: ImmuCell Corporation

Manager TitleAgeSince
Chief Executive Officer - 01/11/2025
Director of Finance/CFO 46 07/04/2025
Comptroller/Controller/Auditor - -

Composition of the Board of Directors: ImmuCell Corporation

Director TitleAgeSince
Chairman 69 21/12/2006
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Director/Board Member 46 01/11/2025
Director/Board Member - 01/11/2025
Director/Board Member 62 01/04/2026
Director/Board Member - 15/04/2026
Director/Board Member - 15/04/2026

Shareholders: ImmuCell Corporation

NameStocks%Valuation
9.205 %
832,790 9.205 % 9 M $
7.119 %
644,019 7.119 % 7 M $
5.682 %
514,003 5.682 % 5 M $
5.552 %
502,258 5.552 % 5 M $
4.442 %
401,819 4.442 % 4 M $

Company details: ImmuCell Corporation

ImmuCell Corp.

56 Evergreen Drive

04103, Portland

+207 878 2770

http://www.immucell.com
address ImmuCell Corporation(ICCC)

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-0.62%+0.73%+51.01%+70.12% 87.57M
-2.41%+0.14%+39.53%+154.43% 1,010B
+1.07%+3.48%+53.75%+50.64% 580B
+1.32%+0.22%+18.35%+65.35% 402B
+0.77%0.00%+19.99%+16.80% 330B
-1.42%-1.44%+45.50%+8.37% 294B
-0.85%-2.86%+22.05%+13.80% 280B
+0.44%+3.48%+24.48%+34.39% 281B
+1.66%+1.20%-44.67%-47.49% 197B
+0.32%+1.61%+19.48%+63.42% 192B
Average -0.32%+0.96%+24.95%+42.98% 356.71B
Weighted average by Cap. -0.80%+1.00%+29.84%+66.16%
  1. Stock Market
  2. Stocks
  3. ICCC Stock
  4. Company ImmuCell Corporation
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!